Stephens started coverage on shares of DENTSPLY SIRONA (NASDAQ:XRAY) in a research note issued to investors on Tuesday morning, Marketbeat Ratings reports. The firm issued an overweight rating and a $75.00 price objective on the medical instruments supplier’s stock.

A number of other research firms also recently issued reports on XRAY. Barrington Research upgraded shares of DENTSPLY SIRONA from a market perform rating to an outperform rating and set a $73.00 price objective on the stock in a research note on Monday, November 6th. TheStreet upgraded shares of DENTSPLY SIRONA from a c rating to a b- rating in a research note on Friday, November 3rd. Stifel Nicolaus increased their price objective on shares of DENTSPLY SIRONA from $66.00 to $70.00 and gave the company a buy rating in a research note on Monday, November 6th. HC Wainwright reiterated a buy rating and set a $68.00 price objective on shares of DENTSPLY SIRONA in a research note on Monday, November 6th. Finally, Zacks Investment Research downgraded shares of DENTSPLY SIRONA from a hold rating to a sell rating in a research note on Monday, October 30th. Three analysts have rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $67.73.

DENTSPLY SIRONA (XRAY) opened at $66.08 on Tuesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.32 and a quick ratio of 1.59. The company has a market cap of $15,391.05, a PE ratio of 26.70, a price-to-earnings-growth ratio of 2.65 and a beta of 1.31. DENTSPLY SIRONA has a one year low of $52.53 and a one year high of $68.98.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 EPS for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.04. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $978.99 million. DENTSPLY SIRONA had a negative net margin of 20.33% and a positive return on equity of 7.56%. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.66 EPS. sell-side analysts anticipate that DENTSPLY SIRONA will post 2.66 earnings per share for the current fiscal year.

In other news, insider Mark Thierer bought 77,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was bought at an average price of $66.04 per share, with a total value of $5,085,080.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Francis J. Lunger sold 8,900 shares of the stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $65.90, for a total transaction of $586,510.00. The disclosure for this sale can be found here. Corporate insiders own 1.99% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. Alps Advisors Inc. lifted its position in DENTSPLY SIRONA by 0.3% during the second quarter. Alps Advisors Inc. now owns 7,523 shares of the medical instruments supplier’s stock valued at $488,000 after acquiring an additional 20 shares during the last quarter. Wetherby Asset Management Inc. lifted its position in DENTSPLY SIRONA by 0.6% during the second quarter. Wetherby Asset Management Inc. now owns 5,004 shares of the medical instruments supplier’s stock valued at $324,000 after acquiring an additional 30 shares during the last quarter. BRYN MAWR TRUST Co lifted its position in DENTSPLY SIRONA by 0.5% during the second quarter. BRYN MAWR TRUST Co now owns 12,064 shares of the medical instruments supplier’s stock valued at $782,000 after acquiring an additional 65 shares during the last quarter. Nordea Investment Management AB lifted its position in DENTSPLY SIRONA by 0.7% during the second quarter. Nordea Investment Management AB now owns 10,235 shares of the medical instruments supplier’s stock valued at $664,000 after acquiring an additional 75 shares during the last quarter. Finally, Security National Bank of Sioux City Iowa IA lifted its position in DENTSPLY SIRONA by 0.4% during the second quarter. Security National Bank of Sioux City Iowa IA now owns 23,081 shares of the medical instruments supplier’s stock valued at $1,497,000 after acquiring an additional 102 shares during the last quarter. 96.59% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.thecerbatgem.com/2017/12/02/dentsply-sirona-xray-now-covered-by-analysts-at-stephens.html.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Stock Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related stocks with our FREE daily email newsletter.